Rodent models of diabetic kidney disease: human translatability and preclinical validity

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Rodent models of diabetic kidney disease : human translatability and preclinical validity. / Sembach, Frederikke E.; Østergaard, Mette V.; Vrang, Niels; Feldt-Rasmussen, Bo; Fosgerau, Keld; Jelsing, Jacob; Fink, Lisbeth N.

I: Drug Discovery Today, Bind 26, Nr. 1, 2021, s. 200-217.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Sembach, FE, Østergaard, MV, Vrang, N, Feldt-Rasmussen, B, Fosgerau, K, Jelsing, J & Fink, LN 2021, 'Rodent models of diabetic kidney disease: human translatability and preclinical validity', Drug Discovery Today, bind 26, nr. 1, s. 200-217. https://doi.org/10.1016/j.drudis.2020.05.004

APA

Sembach, F. E., Østergaard, M. V., Vrang, N., Feldt-Rasmussen, B., Fosgerau, K., Jelsing, J., & Fink, L. N. (2021). Rodent models of diabetic kidney disease: human translatability and preclinical validity. Drug Discovery Today, 26(1), 200-217. https://doi.org/10.1016/j.drudis.2020.05.004

Vancouver

Sembach FE, Østergaard MV, Vrang N, Feldt-Rasmussen B, Fosgerau K, Jelsing J o.a. Rodent models of diabetic kidney disease: human translatability and preclinical validity. Drug Discovery Today. 2021;26(1):200-217. https://doi.org/10.1016/j.drudis.2020.05.004

Author

Sembach, Frederikke E. ; Østergaard, Mette V. ; Vrang, Niels ; Feldt-Rasmussen, Bo ; Fosgerau, Keld ; Jelsing, Jacob ; Fink, Lisbeth N. / Rodent models of diabetic kidney disease : human translatability and preclinical validity. I: Drug Discovery Today. 2021 ; Bind 26, Nr. 1. s. 200-217.

Bibtex

@article{f731c96774ac4bd5bcaab2c6eda6e2f0,
title = "Rodent models of diabetic kidney disease: human translatability and preclinical validity",
abstract = "Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD). Except for SGLT2 inhibitors and GLP-1R agonists, there have been few changes in DKD treatment over the past 25 years, when multifactorial intervention was introduced in patients with type 2 diabetes mellitus (T2DM). The unmet clinical need is partly due to the lack of animal models that replicate clinical features of human DKD, which has raised concern about the utility of these models in preclinical drug discovery. In this review, we performed a comprehensive analysis of rodent models of DKD to compare treatment efficacy from preclinical testing with outcome from clinical trials. We also investigated whether rodent models are predictive for clinical outcomes of therapeutic agents in human DKD.",
author = "Sembach, {Frederikke E.} and {\O}stergaard, {Mette V.} and Niels Vrang and Bo Feldt-Rasmussen and Keld Fosgerau and Jacob Jelsing and Fink, {Lisbeth N.}",
year = "2021",
doi = "10.1016/j.drudis.2020.05.004",
language = "English",
volume = "26",
pages = "200--217",
journal = "Drug Discovery Today: BIOSILICO",
issn = "1359-6446",
publisher = "Elsevier Ltd. * Trends Journals",
number = "1",

}

RIS

TY - JOUR

T1 - Rodent models of diabetic kidney disease

T2 - human translatability and preclinical validity

AU - Sembach, Frederikke E.

AU - Østergaard, Mette V.

AU - Vrang, Niels

AU - Feldt-Rasmussen, Bo

AU - Fosgerau, Keld

AU - Jelsing, Jacob

AU - Fink, Lisbeth N.

PY - 2021

Y1 - 2021

N2 - Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD). Except for SGLT2 inhibitors and GLP-1R agonists, there have been few changes in DKD treatment over the past 25 years, when multifactorial intervention was introduced in patients with type 2 diabetes mellitus (T2DM). The unmet clinical need is partly due to the lack of animal models that replicate clinical features of human DKD, which has raised concern about the utility of these models in preclinical drug discovery. In this review, we performed a comprehensive analysis of rodent models of DKD to compare treatment efficacy from preclinical testing with outcome from clinical trials. We also investigated whether rodent models are predictive for clinical outcomes of therapeutic agents in human DKD.

AB - Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD). Except for SGLT2 inhibitors and GLP-1R agonists, there have been few changes in DKD treatment over the past 25 years, when multifactorial intervention was introduced in patients with type 2 diabetes mellitus (T2DM). The unmet clinical need is partly due to the lack of animal models that replicate clinical features of human DKD, which has raised concern about the utility of these models in preclinical drug discovery. In this review, we performed a comprehensive analysis of rodent models of DKD to compare treatment efficacy from preclinical testing with outcome from clinical trials. We also investigated whether rodent models are predictive for clinical outcomes of therapeutic agents in human DKD.

U2 - 10.1016/j.drudis.2020.05.004

DO - 10.1016/j.drudis.2020.05.004

M3 - Review

C2 - 32413492

AN - SCOPUS:85084974698

VL - 26

SP - 200

EP - 217

JO - Drug Discovery Today: BIOSILICO

JF - Drug Discovery Today: BIOSILICO

SN - 1359-6446

IS - 1

ER -

ID: 251642383